REGENXBIO will file for accelerated approval of the gene therapy to the FDA. Credit: Sheldon Cooper/SOPA Images/LightRocket via REGENXBIO is set to apply for US accelerated approval of its Duchenne ...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ...

Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 ...

Bermuda-based Calidris Investment Partners, an insurance-focused investment manager backed by RedBird Capital Partners, has ...

The closest-ever detailed look at a key enzyme inside the virus that causes COVID-19 could lead to more effective treatment ...

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings Entrada Therapeutics (NASDAQ:TRDA) said initial data from the ...

At a 6 mg/kg dose, ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded ...

Calidris Investment Partners has appointed three new team members as the firm expands its insurance-focused investment ...

A 27-year-old Miami man was arrested Wednesday after police said he slapped his mother, prevented her from leaving their home ...

Entrada said Thursday that Cohort 1 demonstrated an increase of 2.36% in dystrophin over a baseline of 4% and an increase of 2.31% in exon skipping over a baseline of 2.66% in treated participants.

Entrada identified lower-than-expected plasma exposure in juvenile DMD patients as the cause of the lackluster data. Exposure ...

HAMILTON, Bermuda, May 07, 2026 (GLOBE NEWSWIRE) -- (“Calidris”), an insurance-focused investment manager backed by RedBird Capital Partners, today announced three new hires as the firm continues ...